Health technology: AI Speeds Drug Discovery, But Development Bottlenecks Still Rule

AI Speeds Drug Discovery, But Development Bottlenecks Still Rule

247 Health News Editorial

·

22 June 2026

·

3 min read

·healthtech

Computational platforms are generating drug candidates faster than ever — but Phase II and III attrition rates remain stubbornly high. A June 2026 MedCity News analysis argues that development, not discovery, is still the decisive bottleneck in bringing new therapies to patients.

Originally reported by MedCity News

References

  1. 1.Hickman, E. (2026). AI can accelerate discovery — development still decides what advances. MedCity News. https://medcitynews.com/2026/06/ai-can-accelerate-discovery-development-still-decides-what-advances/
  2. 2.Mullard, A. (2023). What is the FDA approving, and why? Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-023-00190-3
  3. 3.Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., & Hassabis, D. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583–589. https://doi.org/10.1038/s41586-021-03819-2
  4. 4.Sun, D., Gao, W., Hu, H., & Zhou, S. (2022). Why 90% of clinical drug development fails and how to improve it? Acta Pharmaceutica Sinica B, 12(7), 3049–3062. https://doi.org/10.1016/j.apsb.2022.02.002
  5. 5.Wouters, O. J., McKee, M., & Luyten, J. (2020). Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA, 323(9), 844–853. https://doi.org/10.1001/jama.2020.1166
  6. 6.Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, 11(3), 191–200. https://doi.org/10.1038/nrd3681
  7. 7.Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., & Schneider, G. (2020). Rethinking drug design in the artificial intelligence era. Nature Reviews Drug Discovery, 19(5), 353–364. https://doi.org/10.1038/s41573-019-0050-3
  8. 8.Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., & Collins, J. J. (2020). A deep learning approach to antibiotic discovery. Cell, 180(4), 688–702.e13. https://doi.org/10.1016/j.cell.2020.01.021
  9. 9.Bender, A., & Cortés-Ciriano, I. (2021). Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. Drug Discovery Today, 26(2), 511–524. https://doi.org/10.1016/j.drudis.2020.12.009
  10. 10.Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., & Pirmohamed, M. (2019). Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery, 18(1), 41–58. https://doi.org/10.1038/nrd.2018.168
Share:XLinkedIn
2

247 Health News Editorial

247 Health News is a medical intelligence platform delivering evidence-based research appraisals, clinical trial monitoring, and health technology news for healthcare professionals.

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service